SecBot SecBot
6-K ·Filed Jun 30, 2026

MESO

MESOBLAST LTD
BULLISH
Impact 6/10
Horizonmonths Processed4mo ago SEC0001345099-26-000062
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor FDA review progress and any updates on modular review acceptance. The RMAT designation allows for rolling and priority review, which could accelerate timeline. Approval would open a new market in LVAD-related complications, but clinical data adequacy remains key.

DirectionBullish
Confidencemedium
Horizonmonths

rexlemestrocel-L

▲ Bullish Named in this 6-K
Impact
Phase
Phase 3 / Filed BLA
Time to market
LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
Next catalyst
None dated

What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$14.09
T+0 close · Jun 30, 2026 · via day close
Latest settled
+9.87%
T+60 · $15.48
Vs SPY
+6.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 1 $14.09entry
  2. T+1 · 5mo ago +2.06%α +2.19% · $14.38
  3. T+5 · 4mo ago +1.42%α +1.16% · $14.29
  4. T+20 · 4mo ago +0.28%α +2.47% · $14.13
  5. T+60 · 8w ago +9.87%α +6.99% · $15.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast received a BLA filing number from the FDA and requested a modular review for rexlemestrocel-L in end-stage heart failure patients with LVADs. The drug has Orphan Drug and RMAT designations, and the company highlighted recent FDA guidance on regulatory flexibility for orphan rare diseases. This is a positive regulatory milestone but does not guarantee approval.

Key Facts

  • Received BLA filing number from FDA for rexlemestrocel-L in end-stage heart failure with LVADs
  • Requested modular review of the BLA
  • Rexlemestrocel-L has Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations
  • FDA recently issued draft guidance on flexibility for demonstrating substantial evidence of effectiveness for orphan rare diseases

Financial Impact

No financial figures disclosed; regulatory milestone with potential future revenue if approved

Risk Factors

  • FDA may not accept modular review or may require additional clinical data
  • Competition from other therapies for LVAD-related gastrointestinal bleeding
  • Commercial adoption depends on pricing and reimbursement

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001345099-26-000062
Exhibit: exhibit991lvadblasubmiss.htm0001345099-26-000062
Document: 0001345099-26-000062-index-headers.html0001345099-26-000062
Document: 0001345099-26-000062-index.html0001345099-26-000062
Document: 0001345099-26-000062.txt0001345099-26-000062

Track record

25 reports on MESO

Performance horizon

6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026